This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
MiPLA: Difference between revisions
>LockPicker m use {{DangerousInteractions/Psychedelics}} |
>LockPicker revised references |
||
| Line 2: | Line 2: | ||
'''N-Methyl-N-isopropyllysergamide''' (also known as '''methylisopropyllysergamide''', '''Lamide''' and '''MiPLA''') is a lesser-known novel [[psychoactive class::psychedelic]] substance of the [[chemical class::lysergamide]] class. MiPLA is structurally related to [[LSD]] and likely has a similar mechanism of action, working primarily by binding to the [[serotonin]]-2A [[receptor]] in the brain.{{citation needed}} | '''N-Methyl-N-isopropyllysergamide''' (also known as '''methylisopropyllysergamide''', '''Lamide''' and '''MiPLA''') is a lesser-known novel [[psychoactive class::psychedelic]] substance of the [[chemical class::lysergamide]] class. MiPLA is structurally related to [[LSD]] and likely has a similar mechanism of action, working primarily by binding to the [[serotonin]]-2A [[receptor]] in the brain.{{citation needed}} | ||
MiPLA was first discovered by Albert Hoffman as a part of the original structure-activity research for [[LSD]].{{citation needed}} It has recently been researched in greater detail by by a team led by David E. Nichols at Purdue University.{{citation needed}} MiPLA and its effects are also mentioned in Alexander Shulgin's "Pharmacology Notes #9" and "Pharmacology Notes C".<ref>https://erowid.org/library/books_online/shulgin_labbooks/shulgin_pharmacology_notebook9_searchable.pdf</ref><ref>https://erowid.org/library/books_online/shulgin_labbooks/shulgin_pharmacology_notebookc_searchable.pdf</ref> According to Shulgin, human subjects administered MiPLA at doses of 180–300 μg experienced LSD-like psychedelic effects, making it about two- to threefold less potent than LSD.<ref>Halberstadt | MiPLA was first discovered by Albert Hoffman as a part of the original structure-activity research for [[LSD]].{{citation needed}} It has recently been researched in greater detail by by a team led by David E. Nichols at Purdue University.{{citation needed}} MiPLA and its effects are also mentioned in Alexander Shulgin's "Pharmacology Notes #9" and "Pharmacology Notes C".<ref>{{cite book|author=Alexander Shulgin|author-link=Alexander Shulgin|title=Pharmacology Notes IX (The Shulgin Lab Books)|publisher=Erowid|url=https://erowid.org/library/books_online/shulgin_labbooks/shulgin_pharmacology_notebook9_searchable.pdf}}</ref><ref>https://erowid.org/library/books_online/shulgin_labbooks/shulgin_pharmacology_notebookc_searchable.pdf</ref> According to Shulgin, human subjects administered MiPLA at doses of 180–300 μg experienced LSD-like psychedelic effects, making it about two- to threefold less potent than LSD.<ref>{{cite journal|last1=Halberstadt|first1=A. L.|last2=Klein|first2=L. M.|last3=Chatha|first3=M.|last4=Valenzuela|first4=L. B.|last5=Stratford|first5=A.|last6=Wallach|first6=Jason|last7=Nichols|first7=D. E.|author-link7=David E. Nichols|last8=Brandt|first8=S. D.|title=Pharmacological characterization of the LSD analog ''N''-ethyl-''N''-cyclopropyl lysergamide (ECPLA)|journal=Psychopharmacology|year=2018|volume=236|pages=799–808|doi=10.1007/s00213-018-5055-9|issn=0033-3158|eissn=1432-2072|oclc=2409222}}</ref> | ||
User reports describe the effects of MiPLA as similar to those of LSD but with some notable differences. It has been described as more mentally and physically oriented than LSD but with a less introspective headspace, accompanied by subtle visuals. It also has a notably shorter duration at around 6 hours and is generally described as less anxiety-provoking than LSD and other lysergamides. | User reports describe the effects of MiPLA as similar to those of LSD but with some notable differences. It has been described as more mentally and physically oriented than LSD but with a less introspective headspace, accompanied by subtle visuals. It also has a notably shorter duration at around 6 hours and is generally described as less anxiety-provoking than LSD and other lysergamides. | ||
| Line 161: | Line 161: | ||
*'''Austria''': MiPLA is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD. {{citation needed}} | *'''Austria''': MiPLA is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD. {{citation needed}} | ||
*'''Germany''': MiPLA is controlled under the NpSG (New Psychoactive Substances Act) | *'''Germany''': MiPLA is controlled under the NpSG (''New Psychoactive Substances Act'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/anlage.html|title=Anlage NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]|access-date=December 10, 2019|language=de}}</ref> as of July 18, 2019.<ref>{{cite web|url=http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl119s1083.pdf|title=Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes|publisher=Bundesanzeiger Verlag|work=Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27|pages=1083-1094|publication-date=July 17, 2019|access-date=January 1, 2020|language=de}}</ref> Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/__4.html|title=§ 4 NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]|access-date=December 10, 2019|language=de}}</ref> | ||
*'''United States''': MiPLA is not scheduled but may be considered to be an analogue of LSD, which would make it illegal to possess for human consumption under the Federal Analogue Act.{{citation needed}} | *'''United States''': MiPLA is not scheduled but may be considered to be an analogue of LSD, which would make it illegal to possess for human consumption under the Federal Analogue Act.{{citation needed}} | ||